


Registration Number 84071


8108789



**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' Report and Financial Statements**

**for the year ended 31 December 2014**



**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Contents**

	<b>Page</b>
Directors and other information	<b>1</b>
Directors' report	<b>2 - 3</b>
Statement of Directors' Responsibilities	<b>4</b>
Independent Auditors' report to the members	<b>5 - 6</b>
Income and expenditure account	<b>7</b>
Balance sheet	<b>8</b>
Cash flow statement	<b>9</b>
Notes to the financial statements including Statement of Accounting Policies	<b>10 - 15</b>

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors and other information**

Directors	Emer Lawlor Michael Cronin Paul Browne Prof Shaun McCann Sheila Sugrue Cedric Robert Sanderson Christie Alan Tate
Secretary	Edward Fleming
Company number	84071
Registered office	1 Terenure Place Terenure Dublin 6W
Auditors	Ryan & Crowley Limited Chartered Accountant & Registered Auditor Abercorn House 57 Charleston Road Ranelagh Dublin 6
Business address	St. James Hospital Dublin 8
Bankers	Allied Irish Bank plc 12 Rathfarnham Rd Terenure Dublin 6
Solicitors	Sherwin O'Riordan 74 Pembroke Row Ballsbridge Dublin 24
Charity Number	20024277

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' report**  
**for the year ended 31 December 2014**

The directors present their report and the audited financial statements for the year ended 31 December 2014.

**Principal activities and review of the business**

The principal activity of the charity is to promote, subscribe to and assist with the provision of Bone Marrow transplantation services for patients in the Republic of Ireland suffering from the medical disease known as Leukaemia and from allied blood disorders. This service is currently based out of St. James Hospital in Dublin City but it is the charity's objective to provide the services to as many Hospitals as possible in the Republic of Ireland.

The charity provides equipment and resources to St James's Hospital for the care of patients suffering from leukaemia. Equipment and resources are also provided to St James Hospital to promote, assist and subscribe to the further education of medical staff in the treatment of patients in the Republic of Ireland who suffer from Leukaemia and allied blood disorder.

Funding is received from donations and fundraising events. The main fundraising events are the organised walks and the mini-marathon. Donations are given to the charity by individuals and organisations. The charity owns eight apartments which the charity provides to patients and their families who are receiving treatment in the hospital. These facilities are provided free of charge to patients and their families.

**Results and dividends**

The results for the year are set out on page .

**Principal risks and uncertainties**

The performance of the company may be adversely affected by a general economic conditions in Ireland. The directors are aware of the major risks to which the company is exposed, in particular those related to the operations and finances of the company and are satisfied that systems are in place to mitigate exposure to major risks. The company's policy is to ensure that sufficient resources are available either from cash balances, cash flows and near cash liquid investments to ensure all obligations can be met when they fall due.

**Research and development**

There was no research or development carried out by the charity during the year.

**Events since the balance sheet date**

There have been no significant events affecting the company since the year end.

**Political donations**

There were no political donations during the year.

**Directors of the Company**

The present membership of the board is listed on the 'Directors and other information' page

The directors are not required to retire from the board by rotation.

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Directors' report**  
**for the year ended 31 December 2014**

..... continued


**Books of account**

The measures taken by the directors to ensure compliance with the requirements of Section 202, Companies Act, 1990, regarding proper books of account are the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel with appropriate expertise and the provision of adequate resources to the financial function. The books of account of the company are maintained at the Registered Office.

**Auditors**

The auditors, Ryan & Crowley Limited, have indicated their willingness to continue in office in accordance with the provisions of Section 160(2) of the Companies Act, 1963.

This report was approved by the Board on 23 April 2015 and signed on its behalf by



**Michael Cronin**  
**Director**



**Prof Shaun McCann**  
**Director**

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Statement of directors responsibilities for the members' financial statements**

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable Irish law and generally accepted accounting practice in Ireland including the accounting standards issued by the Accounting Standards Board and published by the Institute of Chartered Accountants in Ireland.

Irish Company law requires the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the surplus or deficit of the company for that period.

The directors confirm that they have complied with the above requirements in preparing the financial statements.

The directors are responsible for keeping proper books of account which disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements are prepared in accordance with accounting standards generally accepted in Ireland and with Irish statute comprising the Companies Acts, 1963 to 2013. They are also responsible for safeguarding the assets of the company and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the board



**Michael Cronin**  
Director



**Prof Shaun McCann**  
Director

Date: 23rd April 2015

**Independent auditor's report to the members of  
(A Company Limited by Guarantee and not having a Share Capital)**

We have audited the financial statements of Bone Marrow for Leukaemia Trust for the year ended 31 December 2014 which comprise the Income and Expenditure Account, the Balance Sheet, the Cash Flow Statement and the related notes. The financial reporting framework that has been applied in their preparation is Irish law and accounting standards issued by the Financial Reporting Council and promulgated by the Institute of Chartered Accountants in Ireland (Generally Accepted Accounting Practice in Ireland).

This report is made solely to the company's members, as a body, in accordance with Section 193 of the Companies Act, 1990. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

**Respective responsibilities of directors and auditors**

As explained more fully in the Directors' Responsibilities Statement set out on page 4, the directors are responsible for the preparation of the financial statements giving a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with Irish law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

**Scope of the audit of the financial statements**

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the annual report to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

**Opinion on financial statements**

In our opinion the financial statements:

- give a true and fair view, in accordance with Generally Accepted Accounting Practice in Ireland of the state of the company's affairs as at 31 December 2014 and of its profit for the year then ended; and
- have been properly prepared in accordance with the requirements of the Companies Acts 1963 to 2013.

**Matters on which we are required to report by the Companies Acts 1963 to 2013**


- we have obtained all the information and explanations which we consider necessary for the purposes of our audit;
- in our opinion proper books of account have been kept by the company;
- the financial statements are in agreement with the books of account;
- in our opinion the information given in the directors' report is consistent with the financial statements.

**Independent auditor's report to the members of  
(A Company Limited by Guarantee and not having a Share Capital)**

..... continued

**Matters on which we are required to report by exception**

We have nothing to report in respect of the provisions in the Companies Acts 1963 to 2013 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.



**Raymond Ryan**  
for and on behalf of  
**Ryan & Crowley Limited**  
**Chartered Accountant & Registered Auditor**

**Abercorn House**  
**57 Charleston Road**  
**Ranelagh**  
**Dublin 6**

**Date: 23 April 2015**




**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**


**Income and Expenditure Account**  
**for the year ended 31 December 2014**

		<b>Continuing operations</b>	
		<b>2014</b>	<b>2013</b>
	<b>Notes</b>	<b>€</b>	<b>€</b>
Income from fundraising activities	2	423,432	323,105
Expenditure relating to fundraising activities		(119,487)	(87,499)
<b>Net income from fundraising activities</b>		303,945	235,606
Operating and administration expenses		(70,664)	(69,278)
Government grant income released	11	3,809	3,809
Investment income	4	21,250	73,724
<b>Operating surplus/(deficit)</b>		258,340	243,861
Taxation		-	-
<b>Excess of income over expenditure for the year</b>		258,340	243,861
Donations to Hospital and Patient Support		(99,954)	(351,950)
<b>Surplus/(deficit) for the year</b>		<u>158,386</u>	<u>108,089</u>

There are no recognised gains or losses other than the surplus or deficit for the above two financial years.

The financial statements were approved and authorised for issue by the Board on 23 April 2015 and signed on its behalf by

  
**Michael Cronin**  
 Director

  
**Prof Shaun McCann**  
 Director


**The notes on pages 10 to 15 form an integral part of these financial statements.**

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Balance sheet**  
**as at 31 December 2014**

	Notes	2014		2013	
		€	€	€	€
<b>Fixed assets</b>					
Tangible assets	7		1,958,032		1,965,330
Financial assets	8		1,160,600		1,000,000
			<u>3,118,632</u>		<u>2,965,330</u>
<b>Current assets</b>					
Debtors	9	51,971		56,189	
Cash at bank and in hand		803,665		640,767	
		<u>855,636</u>		<u>696,956</u>	
<b>Creditors: amounts falling due within one year</b>	<b>10</b>		<u>(2,579)</u>		<u>(5,773)</u>
<b>Net current assets</b>			<u>853,057</u>		<u>691,183</u>
<b>Total assets less current liabilities</b>			3,971,689		3,656,513
<b>Accruals and deferred income</b>	<b>11</b>		(6,354)		<u>(10,163)</u>
<b>Net assets</b>			<u>3,965,335</u>		<u>3,646,350</u>
<b>Reserves</b>					
Revaluation reserve	12		160,600		-
Revenue reserves account	12		3,804,735		3,646,350
<b>Trusts' total reserves</b>	<b>13</b>		<u>3,965,335</u>		<u>3,646,350</u>

The financial statements were approved and authorised for issue by the Board on 23 April 2015 and signed on its behalf by



**Michael Cronin**  
**Director**



**Prof Shaun McCann**  
**Director**


**The notes on pages 10 to 15 form an integral part of these financial statements.**

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**


**Cash flow statement**  
**for the year ended 31 December 2014**

	Notes	2014 €	2013 €
<b>Reconciliation of operating profit/(loss) to net cash inflow from operating activities</b>			
Operating profit/(loss)		158,386	(108,089)
Deposit interest		1,873	(51,344)
Depreciation		7,297	7,297
Decrease in debtors		4,218	(27,062)
(Decrease) in creditors		(3,194)	(98)
Government grant released		(3,809)	(3,809)
<b>Net cash inflow from operating activities</b>		<u>164,771</u>	<u>(183,105)</u>
<b>Cash flow statement</b>			
Net cash inflow from operating activities		164,771	(183,105)
Returns on investments and servicing of finance	15	(1,873)	51,344
Capital expenditure and financial investment	15	-	(476,366)
<b>Increase in cash in the year</b>		<u>162,898</u>	<u>(608,127)</u>
<b>Reconciliation of net cash flow to movement in net funds (Note 16)</b>			
<b>Increase in cash in the year</b>		162,898	(608,127)
Net cash inflow from issue of shares classed as financial liabilities		-	-
<b>Net funds at 1 January 2014</b>		<u>640,767</u>	<u>1,248,894</u>
<b>Net funds at 31 December 2014</b>		<u>803,665</u>	<u>640,767</u>

The financial statements were approved and authorised for issue by the Board on 23 April 2015 and signed on its behalf by



**Michael Cronin**  
**Director**



**Prof Shaun McCann**  
**Director**

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2014**

**1. Statement of accounting policies**

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

**1.1. Basis of preparation**

The audited financial statements have been prepared in accordance with accounting standards generally accepted in Ireland and Irish statute comprising the Companies Acts, 1963 to 2013, Accounting Standards generally accepted in Ireland in preparing financial statements giving a true and fair view are those issued by the Accounting Standards Board.

**1.2. Income Policy**

Income represents the total number of donations and fundraising received and lodged to the company's bank accounts.

**1.3. Tangible fixed assets and depreciation**

Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment loss. Cost includes all costs that are directly attributable to bringing the asset into working condition for its intended use.

**Depreciation**

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset systematically over its expected useful life, as follows:

Fixtures, fittings and equipment	-	10% Straight Line
-------------------------------------	---	-------------------

**1.4. Financial assets**

Fixed asset investments are stated at cost less provision for permanent diminution in value. Investments are reviewed for diminution in value if events or changes in circumstances indicate that the carrying amount may not be recoverable. Diminution in value is calculated such that carrying value of the fixed asset investment is the lower of its cost or recoverable amount. Recoverable amount is the higher of its net realisable value and its value in use.

**1.5. Taxation**

The yearly charge for taxation is based on the profit for the year and is calculated with reference to the tax rates applying at the balance sheet date.

**1.6. Government grants**

Grants are credited to deferred revenue. Grants towards capital expenditure are released to the profit and loss account over the expected useful life of the assets. Grants towards revenue expenditure are released to the profit and loss account as the related expenditure is incurred.

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2014**

..... continued

**2. Income**

The charities streams of income include donations/fundraising, mini-marathon, big wheel, christmas card, walk receipts and other events.

**3. Auditors' remuneration**

	2014	2013
	€	€
Auditors' remuneration		
Audit of the financial statements	3,075	3,075
	<u>3,075</u>	<u>3,075</u>

**4. Income from investments**

	2014	2013
	€	€
Deposit interest	(1,873)	51,344
Rental income	23,123	22,380
	<u>21,250</u>	<u>73,724</u>

**5. Employees**

**Number of employees**

The average monthly numbers of employees (including the directors) during the year were:

	2014	2013
Directors	<u>7</u>	<u>6</u>

**6. Transactions with directors**

There were no related party transactions with the directors during the period.

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2014**

..... continued

<b>7. Tangible fixed assets</b>	<b>Land and buildings freehold</b>	<b>Fixtures, fittings and equipment</b>	<b>Total</b>
	<b>€</b>	<b>€</b>	<b>€</b>
<b>Cost/revaluation</b>			
At 1 January 2014	1,912,642	266,962	2,179,604
At 31 December 2014	<u>1,912,642</u>	<u>266,962</u>	<u>2,179,604</u>
<b>Depreciation</b>			
At 1 January 2014	-	214,275	214,275
Charge for the year	-	7,297	7,297
At 31 December 2014	<u>-</u>	<u>221,572</u>	<u>221,572</u>
<b>Net book values</b>			
At 31 December 2014	<u>1,912,642</u>	<u>45,390</u>	<u>1,958,032</u>
At 31 December 2013	<u>1,912,642</u>	<u>52,687</u>	<u>1,965,330</u>
<b>8. Financial assets</b>	<b>Other unlisted investments</b>	<b>Total</b>	
	<b>€</b>	<b>€</b>	
<b>Cost</b>			
At 1 January 2014	1,000,000	1,000,000	
Revaluations	160,600	160,600	
At 31 December 2014	<u>1,160,600</u>	<u>1,160,600</u>	
<b>Net book values</b>			
At 31 December 2014	<u>1,160,600</u>	<u>1,160,600</u>	
At 31 December 2013	<u>1,000,000</u>	<u>1,000,000</u>	
<b>9. Debtors</b>	<b>2014</b>	<b>2013</b>	
	<b>€</b>	<b>€</b>	
Prepayments and accrued income	<u>51,971</u>	<u>56,189</u>	

**Bone Marrow for Leukaemia Trust**  
(A Company Limited by Guarantee and not having a Share Capital)

**Notes to the financial statements**  
**for the year ended 31 December 2014**

..... continued

<b>10. Creditors: amounts falling due within one year</b>	<b>2014</b> €	<b>2013</b> €	
<i>Other creditors</i>			
Accruals and deferred income	2,579	5,773	
	<u>          </u>	<u>          </u>	
<b>11. Accruals and deferred income</b>	<b>2014</b> €	<b>2013</b> €	
<b>Government grants</b>			
At 1 January 2014	10,163	13,972	
Released in year	(3,809)	(3,809)	
At 31 December 2014	<u>6,354</u>	<u>10,163</u>	
<b>12. Equity Reserves</b>	<b>Revaluation reserve</b> €	<b>Revenue reserve</b> €	<b>Total</b> €
<b>At 1 January 2014</b>	-	3,646,349	3,646,349
Surplus/(deficit) for the year	-	158,386	158,386
Other movements	160,600	-	160,600
<b>At 31 December 2014</b>	<u>160,600</u>	<u>3,804,735</u>	<u>3,965,335</u>
<b>13. Reconciliation of movements in members' funds</b>	<b>2014</b> €	<b>2013</b> €	
Surplus/(deficit) for the year	158,386	(108,089)	
Other recognised gains or losses	160,600	-	
Net addition to members' funds	318,986	(108,089)	
Opening members' funds	3,646,350	3,754,439	
Closing members' funds	<u>3,965,335</u>	<u>3,646,350</u>	

**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2014**

..... continued

**14. Contingent liabilities**

During the year the Trust contracted with Trinity College Dublin to fund research of Leukaemia and related illnesses at a cost of €250,000 per annum for a three year period.

**15. Gross cash flows**

	2014	2013
	€	€
<b>Returns on investments and servicing of finance</b>		
Interest received	(1,873)	51,344
	<u>          </u>	<u>          </u>
<b>Capital expenditure and financial investment</b>		
Payments to acquire tangible assets	-	(18,456)
Payments to acquire investments	-	(500,000)
Receipts from sales of tangible assets	-	42,090
	<u>          </u>	<u>          </u>
	<u>          </u>	<u>          </u>
	-	(476,366)

**16. Analysis of changes in net funds**

	Opening balance	Cash flows	Closing balance
	€	€	€
Cash at bank and in hand	640,767	162,898	803,665
<b>Net funds</b>	<u>640,767</u>	<u>162,898</u>	<u>803,665</u>

**17. Company Limited by Guarantee**

The company is one limited by guarantee not having a share capital. The liability of each member, in the event of the company being wound up is €6.35

**18. Accounting Periods**

The current accounts are for a full year. The comparative accounts are for a full year.



**Bone Marrow for Leukaemia Trust**  
**(A Company Limited by Guarantee and not having a Share Capital)**

**Notes to the financial statements**  
**for the year ended 31 December 2014**

..... continued

**19. Approval of financial statements**

The board of directors approved these financial statements for issue on 23 April 2015.

10